Rational Drug Design Rational Drug Design: One Target, Many Paths to It

View Sample PDF

Author(s): Khaled H. Barakat (University of Alberta, Canada & Fayoum University, Egypt), Michael Houghton (University of Alberta, Canada), D. Lorne Tyrrel (University of Alberta, Canada)and Jack A. Tuszynski (University of Alberta, Canada)
Copyright: 2017
Pages: 31
Source title: Pharmaceutical Sciences: Breakthroughs in Research and Practice
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-5225-1762-7.ch044

Keywords: Medical Information Science Reference / Medicine & Healthcare / Pharmacology

Purchase

View Rational Drug Design Rational Drug Design: One Target, Many Paths to It on the publisher's website for pricing and purchasing information.

Abstract

For the past three decades rationale drug design (RDD) has been developing as an innovative, rapid and successful way to discover new drug candidates. Many strategies have been followed and several targets with diverse structures and different biological roles have been investigated. Despite the variety of computational tools available, one can broadly divide them into two major classes that can be adopted either separately or in combination. The first class involves structure-based drug design, when the target's 3-dimensional structure is available or it can be computationally generated using homology modeling. On the other hand, when only a set of active molecules is available, and the structure of the target is unknown, ligand-based drug design tools are usually used. This review describes some recent advances in rational drug design, summarizes a number of their practical applications, and discusses both the advantages and shortcomings of the various techniques used.

The IRMA Community

Research IRM

Rational Drug Design Rational Drug Design: One Target, Many Paths to It

Purchase

Abstract

Related Content

IRMA Sponsors